Immunicon — Investor Presentation (November 2004)
28 slides from Immunicon's investor presentation, Nov 19, 2004
Slide 1: Immunicon Management Presentation November 2004
) IMMUNICON Celfular Information for Better Healthcare Management Presentation November 2004
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation may contain forward-looking statements that reflect management’s current views and opinions as to the status of the Company’s products, clinical trials, regulatory approval process, product development, research programs and other future events and operat
Slide 3: Section 1: Company Overview
SECTION 1 Company Overview
Slide 4: Company Overview
Company Overview Immunicon develops and is commercializing products for rare cell analysis @ All FDA clearances for initial products received IVD commercialization in progress Strategic alliance with Johnson & Johnson in cancer High impact clinical diagnostic products Large initial market opportunit
Slide 5: Link to searchable text of slide shown above
Link to searchable text of slide shown above
Slide 6: The Problem
The Problem Select and Monitor Therapy in Metastatic Disease Risk Assessment and Early Detection Monitor Effectiveness of Post-Surgical Therapy and Recurrence Diagnosis, Staging and Selection of Primary Therapy @ IMMUNICON
Slide 7: Section 2: Technology and Products
SECTION2 Technology and Products
Slide 8: "Real-Time Biopsy" Using a Blood Sample
“Real-Time Biopsy” Using a Blood Sample Circulating Tumor Cells (CTCs) Assess Prognosis Count => Direct Therapy Monitor Disease Phenotype Diagnose & Genotype = Specify Therapy Determine F Risk Assessment “Presence ad for Cancer Most tumors are of epithelial cell origin: Isolation of epithelial cells
Slide 9: CellTracks Technology
CellTracks® Technology ‘cellsave | Geelitracks — acwereton Cell Search s Kits & Markers | 4cellspotter Acelitracks Feelltracks ° @ IMMUNICON
Slide 10: A New Paradigm for Cancer Disease Management
A New Paradigm for Cancer Disease Management Current standard: Potential future standard: Radiologist measures changes in Number and/or makeup of CTCs better Jesions on a CT scan to assess reflects efficacy of treatment tumor burden increase/decrease Subjective and semi-quantitative Objective and qu
Slide 11: NEJM 8/19/04: CTCs Predict Survival
10 NEJM 8/19/04: | CTCs Predict Survival %Probability of Survival 100% -| 90%] 80% 70%-| 60% 4 50% 4 40%] 30% -] 20% -| 10%- 0% Before initiation of therapy >18 months 10.1 months : >5CTCs (N=87) N=177 Logrank <0.0001 5 10 15 20 25 30 95 40 45 50 §5 60 65 70 75 80 Time from start of therapy (Weeks)
Slide 12: NEJM 8/19/04: CTCs Predict Response to Therapy
NEJM 8/19/04: CTCs Predict Response to Therapy %Probability of Survival 100% + 90%) 80%] 70%-| 60%) 50%] 40%] 30%] 20%) 10% 0% ~4 weeks after initiation of therapy >18 Months 7.0 months : : >5 CTCs (N=49) N=163 Logrank <0.0001 0° 5 1015 20'25'90 95 40 45 50 55 60 65 70 75 80 Time from 1st Follow-Up
Slide 13: NEJM 8/19/04: Proven Clinical Utility
NEJM 8/19/04: Proven Clinical Utility Current measures to determine if therapy is effective are inadequate, especially early on in the treatment regimen Circulating tumor cells (CTCs) may provide early evidence of therapeutic futility @CTCs are an independent prognostic indicators of favorable & unf
Slide 14: New FDA Classification
® New FDA Classification Classification under “de novo” process: @ Simplifies and shortens regulatory timelines @ 510(k) versus PMA process @ Creates a significant barrier to entry FDA cleared labeling: @ The presence of CTC[s] in the peripheral blood, as detected by the CellSearch™ Circulating Tumo
Slide 15: "Real-Time Biopsy" from a Blood Sample
“Real-Time Biopsy” from a Blood Sample Enables selection of targeted therapies Taxol Ug Herceptin 225 a a So or! 175 150 : 125 BB tera +++ OJ Hera ++ Oo Her2 + [| Her2 - 50 4 = a4 0 Lal = = 0123 4 5 6 7 8 9 101112 13 14 15 16 17 18 19 20 Time (weeks) > CTC Count / 7.5ml Blood IntsOncol 24: 4111-4118
Slide 16: Many Product Opportunities
6 Many Product Opportunities @ Follow-on CTC applications — Other carcinomas — colorectal, prostate, other carcinomas... — Other settings — diagnosis, recurrence, risk assessment... — Nucleic acid and protein cellular markers @ Endothelial cells — Cancer — angiogenesis — Cardiovascular, autoimmune,.
Slide 17: Circulating Endothelial Cells (CECs)
Circulating Endothelial Cells (CECs) CECs are implicated in cancer, cardiovascular disease, and many other diseases and conditions CECs detected by Immunicon system 4 © IMMUNICON
Slide 18: Section 3: Commercialization
SECTIONS Commercialization
Slide 19: Significant Market Opportunity
1° Significant Market Opportunity Overall U.S. Market ¢ Cancer is the second leading killer — Prevalence: 8.9 million survivors — Incidence: 1.3 million new diagnoses p.a. — Mortality: 500,000 deaths p.a. ~86% of all cancers are carcinomas (solid tumors) — CellSearch™ System is “pan-carcinoma” Breas
Slide 20: Strategic Alliance in Cancer with Johnson & Johnson
10 Strategic Alliance in Cancer with Johnson & Johnson Key elements: @ Immunicon develops and manufactures @ J&J finishes, sells and services Revenue shared (~30% to IMMC on reagents) @ Access to J&J technology, expertise and distribution @ Large equity investment by J&J Development Corp. @ IMMUNICO
Slide 21: Selling the Benefits — Product Positioning
2 Selling the Benefits — Product Positioning Blood test @ Predictive = real impact in oncology @ “Real-time biopsy” = real-time medicine @ Minimally invasive Convenient and cost-effective Fully integrated system Automation and standardization @ IMMUNICON
Slide 22: Sales and Marketing Strategy
2 Sales and Marketing Strategy Surgeons Oncologists © IMMUNICON
Slide 23: Section 4: Financial Overview and Milestones
SECTION 4 Financial Overview and Milestones
Slide 24: Attractive Business Model
Attractive Business Model Everybody wins @ List price for instrument system (AP + CS) - $120,000 @ Fast payback for the hospital @ List price for CTC test - $175.00 @ High revenue and margins for J&J and Immunicon Key Drivers for Reimbursement Clinical data to support improved patient outcomes Cost-
Slide 25: Financial Summary
24 Financial Summary $60.3 million cash and cash equivalents @ September 30 @ Cash expenditures for full year 2004 $ 30 million Expenditures through September 30 $ 17.5 million Shares outstanding at September 30 23.1 million @ IVD product launched # Share of revenue on sales of cancer-related produc
Slide 26: Milestones
2 Milestones @ Initial Public Offering Q2 @ Publication in New England Journal of Medicine Q3 @ U.S. in vitro diagnostic (IVD) launch Q3 @ Units shipped to U.S. reference/hospital labs Q3 ~ Announced deal with Quest Diagnostics @ Units shipped to Europe and Japan (RUO) Q2/Q3 @ Systems placed — 7 cus
Slide 27: Investment Highlights
2 Investment Highlights @ Commercialization process well underway Address unmet medical needs in large markets, starting with cancer Strategic partnership in cancer with Johnson & Johnson ~ Compelling clinical data presented at ASCO/NEJM ~ FDA clearances received/passed inspection - ISO 13485:2003 c
Slide 28: Searchable text section of graphics shown above
Searchable text section of graphics shown above [LOGO] Cellular Information for Better Healthcare Management Presentation November 2004 For ward Looking Statements This presentation may contain forward-looking statements that reflect management’s current views and opinions as to the status of the Co